GC Biopharma

GC Biopharma AAQS

The The AAQS of GC Biopharma (006280.KS) as of Nov 22, 2026 is 3. In the previous year, The AAQS was 3.00 — a change of 0.00% (lower).

AAQS

3

YoY

0.00%

Last updated:

GC Biopharma has a current AAQS of 3.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock GC Biopharma in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The GC Biopharma AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
3.00 KRW
Jan 1, 2019
3.00 KRW
Jan 1, 2020
3.00 KRW
Jan 1, 2021
3.00 KRW
Jan 1, 2022
3.00 KRW
Jan 1, 2023
3.00 KRW
Jan 1, 2024
3.00 KRW
Jan 1, 2025
3.00 KRW
The GC Biopharma AAQS history
YEARAAQSYoY
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
30.00%
3—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GC Biopharma Stock analysis

What does GC Biopharma do? GC Biopharma Corp generates revenue through the production and sale of pharmaceutical products such as blood products, general products, vaccines, over-the-counter drugs, diagnostic reagents, placental injections, cell therapies, and blood diagnostic products. The company also offers genome analysis services. Its primary customers include healthcare providers and institutions requiring pharmaceuticals and diagnostic solutions. The firm targets segments focused on biopharmaceutical manufacturing and genomic healthcare services. Green Cross Corp, the parent company, operates under the same business model, emphasizing pharmaceutical manufacturing and genomic services. The company's product portfolio spans blood-related treatments, vaccines, and advanced diagnostic tools, catering to both general medical needs and specialized healthcare applications. Revenue streams are derived from direct sales of these products and services to healthcare sectors. The business model integrates the production of traditional pharmaceuticals with innovative genomic services, creating a diversified revenue base. Key segments include blood product manufacturing, vaccine development, and diagnostic reagent sales, alongside cell therapy and placental injection offerings. Customers are primarily healthcare institutions and providers seeking comprehensive pharmaceutical and diagnostic solutions. GC Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Biopharma stock

The AAQS of GC Biopharma is 3 in 2025.

On Eulerpool you can find the complete historical development of The AAQS GC Biopharma since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — GC Biopharma

All Key Metrics — GC Biopharma